Scroll Down

GAIA
NK-like cell
platform

A breakthrough in
eliminating solid tumors

A major limitation of adoptive cell immunotherapy is its insufficient therapeutic efficacy, even with the use of genetically modified chimeric antigen receptor (CAR)-T and natural killer (NK) cells.
Our platform enables the production of NK-like cells that effectively eliminate solid tumors, without any genetic modification.

Core Technology I
GAAAP

GAIA's antibody-anchoring
and activating peptide

A peptide-based platform
to generate GAIA NK-like cells
targeting a variety of tumors

GAAAP enables the generation of GAIA NK-like cells that maintain their active state in vivo and specifically target cancer cell-expressed proteins.

Core Technology II

News

View all